These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19373666)

  • 21. Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
    Braulke F; Schulz X; Germing U; Schuler E; Platzbecker U; Nolte F; Hofmann WK; Giagounidis A; Götze K; Lübbert M; Schlenk RF; Schanz J; Bacher U; Ganser A; Büsche G; Letsch A; Schafhausen P; Bug G; Brümmendorf TH; Haas R; Trümper L; Shirneshan K; Haase D
    Ann Hematol; 2017 Jun; 96(6):887-894. PubMed ID: 28374162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second complete remission in an elderly patient with acute myeloid leukemia retreated with decitabine.
    Cashen AF; Devine H; DiPersio J
    Am J Hematol; 2006 Jul; 81(7):543-5. PubMed ID: 16755561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
    List A; Dewald G; Bennett J; Giagounidis A; Raza A; Feldman E; Powell B; Greenberg P; Thomas D; Stone R; Reeder C; Wride K; Patin J; Schmidt M; Zeldis J; Knight R;
    N Engl J Med; 2006 Oct; 355(14):1456-65. PubMed ID: 17021321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenalidomide in del 5q MDS: responses and side effects revisited.
    Tiu RV; Sekeres MA
    Leuk Res; 2011 Nov; 35(11):1440-1. PubMed ID: 21764127
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of Decitabine Combined with Unrelated Cord Blood Transplantation in an Adult Patient with -7/EVI1+ Acute Myeloid Leukemia: a Case Report and Literature Review.
    Jiang YZ; Su GP; Dai Y; He HS; Huang LQ; Sun ZM; Huang DP
    Ann Clin Lab Sci; 2015; 45(5):598-601. PubMed ID: 26586716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
    Azaceta G; Calasanz MJ; Dourdil V; Bonafonte E; Izquierdo I; Palomera L
    Leuk Lymphoma; 2010 Oct; 51(10):1941-3. PubMed ID: 20846100
    [No Abstract]   [Full Text] [Related]  

  • 27. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.
    Giagounidis AA; Kulasekararaj A; Germing U; Radkowski R; Haase S; Petersen P; Göhring G; Büsche G; Aul C; Mufti GJ; Platzbecker U
    Leukemia; 2012 Apr; 26(4):855-8. PubMed ID: 21960245
    [No Abstract]   [Full Text] [Related]  

  • 28. A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission.
    Boumber Y; Kantarjian H; Jorgensen J; Wen S; Faderl S; Castoro R; Autry J; Garcia-Manero G; Borthakur G; Jabbour E; Estrov Z; Cortes J; Issa JP; Ravandi F
    Leukemia; 2012 Nov; 26(11):2428-31. PubMed ID: 22665218
    [No Abstract]   [Full Text] [Related]  

  • 29. Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.
    Oka S; Ono K; Nohgawa M
    Ann Hematol; 2017 Aug; 96(8):1411-1413. PubMed ID: 28577044
    [No Abstract]   [Full Text] [Related]  

  • 30. CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT.
    Ford CD; Asch J; Konopa K; Petersen FB
    Bone Marrow Transplant; 2010 Feb; 45(2):403-4. PubMed ID: 19597424
    [No Abstract]   [Full Text] [Related]  

  • 31. Durable complete remission after single agent decitabine in AML relapsing in extramedullary sites after allo-SCT.
    Singh SN; Cao Q; Gojo I; Rapoport AP; Akpek G
    Bone Marrow Transplant; 2012 Jul; 47(7):1008-9. PubMed ID: 22080965
    [No Abstract]   [Full Text] [Related]  

  • 32. Novel agents for the treatment of acute myeloid leukemia in the older patient.
    Baer MR; Gojo I
    J Natl Compr Canc Netw; 2011 Mar; 9(3):331-5. PubMed ID: 21393442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on the pharmacotherapy for myelodysplastic syndromes.
    Duong VH; Komrokji RS; List AF
    Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
    Loiseau C; Ali A; Itzykson R
    Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
    Stone R; Sekeres M; Garcia-Manero G; Lyons RM
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-15. PubMed ID: 19385003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Myelodysplastic syndromes: therapeutic advances and promising future].
    Nomdedeu B
    Med Clin (Barc); 2008 Oct; 131(13):500-2. PubMed ID: 19007578
    [No Abstract]   [Full Text] [Related]  

  • 37. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
    Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
    Tibes R; Al-Kali A; Oliver GR; Delman DH; Hansen N; Bhagavatula K; Mohan J; Rakhshan F; Wood T; Foran JM; Mesa RA; Bogenberger JM
    J Hematol Oncol; 2015 Oct; 8():114. PubMed ID: 26483188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide induces remission and mixed quantitative chimerism fluctuations in refractory and relapsed myeloid malignancy with del (5).
    Dumas PY; Pigneux A; Tabrizi R; Milpied N
    Leuk Res; 2010 Nov; 34(11):e302-3. PubMed ID: 20650527
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
    Khan N; Hantel A; Knoebel RW; Artz A; Larson RA; Godley LA; Thirman MJ; Liu H; Churpek JE; King D; Odenike O; Stock W
    Leuk Lymphoma; 2017 Sep; 58(9):1-7. PubMed ID: 28278716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.